Ascendis Pharma A/S (ASND)

247.91USD -0.58% (-1.45)

Over 1M: +1.6%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

245 250 255 260
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q1 '21 — Gross Profit: 746K Q2 '21 — Gross Profit: 1M Q3 '21 — Gross Profit: 1.1M Q4 '21 — Gross Profit: 1.4M Q1 '22 — Gross Profit: 2.6M Q2 '22 — Gross Profit: 5.1M Q3 '22 — Gross Profit: 13.6M Q4 '22 — Gross Profit: 17.8M Q1 '23 — Gross Profit: 29M Q2 '23 — Gross Profit: 34.5M Q3 '23 — Gross Profit: 40.6M Q4 '23 — Gross Profit: 118.2M Q1 '24 — Gross Profit: 88.3M Q2 '24 — Gross Profit: 24.5M Q3 '24 — Gross Profit: 46.6M Q4 '24 — Gross Profit: 159.9M Q1 '25 — Gross Profit: 83.4M Q2 '25 — Gross Profit: 126.6M Q3 '25 — Gross Profit: 191.3M Q4 '25 — Gross Profit: 223.9M 0 50M 100M 150M 200M 250M
Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25
Gross Profit

Figures as at 2025-12-31, reported in EUR. The newest fact in the filings is dated 2025-12-31, 243 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.3
SBC / sales 16.1%
OE margin -8.6%
Oper. margin -18.9%
ROIC -20.6%
Accruals -21.6%
Gross margin 86.8%
FCF margin 7.5%
OCF margin 7.5%
EBITDA margin -16.5%
Profit margin -31.7%
ROA -17.5%
ROCE -58.4%
Capex / sales —
OCF / EBIT —
ROE —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

1.6
EV/Sales 20.6×
EV/OE -238.4×
P/C 23.0×
EV/GP 23.7×
FCF yield 0.38%
Div. yield —
EV/EBIT —
Fwd P/E —
P/B —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.2
ND/EBITDA -0.046
Interest cover -0.66×
Cash / Debt 0.47×
Quick ratio 0.76×
Debt payback 12.7 yr
Cash runway —
Debt / Eq —
Equity / Assets —
F-score —
Net debt / Eq —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +89.2%
Sales Q/Q +42.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.